CTLA4 and melanoma: Moreover, transcriptomic and methylation levels of CTLA4 can be used for the same purpose in melanoma patients (Goltz et al., 2018; Mo et al., 2018), thereby providing critical references for selection of cancer patients likely to respond to ICIs.